These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1489195)

  • 1. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.
    Christensson BA; Nilsson-Ehle I; Ljungberg B; Lindblad A; Malmborg AS; Hjelte L; Strandvik B
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2512-7. PubMed ID: 1489195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection.
    Strandvik B; Hjelte L; Lindblad A; Ljungberg B; Malmborg AS; Nilsson-Ehle I
    Scand J Infect Dis Suppl; 1989; 60():84-8. PubMed ID: 2756354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
    Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
    Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
    Schaefer HG; Stass H; Wedgwood J; Hampel B; Fischer C; Kuhlmann J; Schaad UB
    Antimicrob Agents Chemother; 1996 Jan; 40(1):29-34. PubMed ID: 8787874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients.
    Steen HJ; Scott EM; Stevenson MI; Black AE; Redmond AO; Collier PS
    J Antimicrob Chemother; 1989 Nov; 24(5):787-95. PubMed ID: 2599998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
    Goldfarb J; Stern RC; Reed MD; Yamashita TS; Myers CM; Blumer JL
    Am J Med; 1987 Apr; 82(4A):174-9. PubMed ID: 3555032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning.
    Redmond A; Sweeney L; MacFarland M; Mitchell M; Daggett S; Kubin R
    J Int Med Res; 1998 Dec; 26(6):304-12. PubMed ID: 10399112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ciprofloxacin: an alternative oral treatment in respiratory Pseudomonas infection in cystic fibrosis].
    Magni A; Pradal U; Cazzola G; Mastella G
    Pediatr Med Chir; 1990; 12(5):531-4. PubMed ID: 2087426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
    Stockmann C; Sherwin CM; Zobell JT; Young DC; Waters CD; Spigarelli MG; Ampofo K
    Pediatr Pulmonol; 2013 Mar; 48(3):211-20. PubMed ID: 22949224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.
    Payen S; Serreau R; Munck A; Aujard Y; Aigrain Y; Bressolle F; Jacqz-Aigrain E
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3170-8. PubMed ID: 14506027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
    Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
    Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ciprofloxacin in cystic fibrosis.
    Davis RL; Koup JR; Williams-Warren J; Weber A; Heggen L; Stempel D; Smith AL
    Antimicrob Agents Chemother; 1987 Jun; 31(6):915-9. PubMed ID: 3619423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
    LeBel M
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):316-24. PubMed ID: 1907546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.
    Hodson ME; Roberts CM; Butland RJ; Smith MJ; Batten JC
    Lancet; 1987 Jan; 1(8527):235-7. PubMed ID: 2880066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin therapy in cystic fibrosis.
    Scully BE; Nakatomi M; Ores C; Davidson S; Neu HC
    Am J Med; 1987 Apr; 82(4A):196-201. PubMed ID: 3555036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of ciprofloxacin in children with cystic fibrosis.
    Orenstein DM; Pattishall EN; Noyes BE; Kurland G; Hartigan ER; Yu VL
    Clin Pediatr (Phila); 1993 Aug; 32(8):504-6. PubMed ID: 8403750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.